A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
暂无分享,去创建一个
Nelson B Rodrigues | R. McIntyre | M. Vinberg | J. Rosenblat | D. Cha | R. Ho | R. Mansur | Yena Lee | Mehala Subramaniapillai | Kangguang Lin | Orly Lipsitz | Kevin Kratiuk | Margarita Shekotikhina | H. Gill
[1] Nelson B Rodrigues,et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. , 2020, Journal of affective disorders.
[2] Nelson B Rodrigues,et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence , 2020, Expert opinion on drug safety.
[3] C. Loo,et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study , 2020, European Archives of Psychiatry and Clinical Neuroscience.
[4] R. Sutar,et al. Pharmacotherapy for dissociative disorders: A systematic review , 2019, Psychiatry Research.
[5] D. M. Lyons,et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism , 2019, Molecular Psychiatry.
[6] R. Shelton,et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.
[7] J. Talbot,et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. , 2019, The American journal of psychiatry.
[8] M. Fava,et al. Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) , 2018, Molecular Psychiatry.
[9] S. Wilkinson,et al. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. , 2018, The Journal of clinical psychiatry.
[10] E. Ballard,et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. , 2018, Journal of affective disorders.
[11] L. Davidson,et al. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. , 2018, Journal of affective disorders.
[12] Kelly C. Lee,et al. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. , 2017, Journal of affective disorders.
[13] E. Ballard,et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.
[14] R. McIntyre,et al. Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[15] M. Frye,et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.
[16] D. Luckenbaugh,et al. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. , 2017, Journal of affective disorders.
[17] Trina E. Chang,et al. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation , 2017, The Australian and New Zealand journal of psychiatry.
[18] Husseini Manji,et al. Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.
[19] M. Frye,et al. Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development , 2015, Journal of clinical psychopharmacology.
[20] K. Laws,et al. The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.
[21] D. Charney,et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. , 2015, The Journal of clinical psychiatry.
[22] D. Luckenbaugh,et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? , 2014, Journal of affective disorders.
[23] R. Lewis‐Fernández,et al. Dissociative disorders in DSM‐5 , 2011, Annual review of clinical psychology.
[24] Sidney Kennedy,et al. Assessing full remission. , 2002, Journal of psychiatry & neuroscience : JPN.
[25] A. Rush,et al. When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.
[26] C. Loo,et al. Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.
[27] S. Southwick,et al. Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.